About
GluGene
Vision
TARGETing Gene Therapies
to Everybody
GluGene Therapeutics offers innovative AAV gene therapy products for incurable diseases by vector engineering and process engineering technologies.
The key platform technology described by TARGET (Transforming AAV by Revolutionary Glue and Evolution Technology) maximizes the therapeutic capacity of AAVs by novel proprietary strategies to address intrinsic problems of the viral vectors. GluGene’s technology unparallelly expands current therapeutic regimes by ‘3E’ advanced approaches: Enhancement of organ specificity, Evasion of neutralizing antibody, and Expansion of therapeutic payloads. Furthermore, collaborative spirit of GluGene team welcomes constructive co-work.
History
2014.04
The promotion of human neural stem cells adhesion using bioinspired poly(norepinephrine) nanoscale coating
Journal of Nanomaterials (2014)
2015.05
SpONGE: spontaneous organization of numerous-layer generation by electrospray
Angewandte Chemie (2015)
2016.07
PEGylation and HAylation via catechol: α-amine-specific reaction at N-terminus of peptides and proteins
Acta Biomaterialia (2016)
2017.08
Inverted quasi-spherical droplets on polydopamine-TiO2 substrates for enhancing gene delivery
Macromolecular Bioscience (2017)
2017.09
Functional polysaccharide sutures prepared by wet fusion of interfacial polyelectrolyte complexation fibers
Advanced Functional Materials (2017)
2021.01
Foundation of
GluGene Therapeutics Inc.
2021.10
Seed investment
2021.09
Pastable, Adhesive, Injectable, Nanofibrous, and Tunable (PAINT) Biphasic Hybrid Matrices as Versatile Therapeutic Carriers
ACS applied materials & interfaces (2021)
2022.09
Establishment of research center
2023.04
KDDF project involvement
2023.05
Distinguishing between DNA-Loaded Full and Empty Capsids of Adeno-Associated Virus with Atomic Force Microscopy imaging
Langmuir (2023)
2023.07
Certificate of Venture Business
2024.03
Enhancing the Production of Adeno-Associated Virus (AAV)2 and AAV9 with High Full Capsid Ratio in HEK293 Cells through Design-of-Experiment Optimization of Triple Plasmid Ratio
Biotechnology Journal (2024)
Leadership
CEO
GluGene Therapeutics Inc.
CTO
GluGene Therapeutics Inc.
Vice President
CJ Pharma, CJ America
Copyright ©2023 GluGene Therapeutics Inc. ALL RIGHTS RESERVED